Physician profile
Marlene E Morales
NPI 1336349117
$4,713.50
in general payments reported to CMS, 2019-2025
25 companies · $739 in 2025
The $739 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $224 · 2021: $247 · 2022: $1,627 · 2023: $899 · 2024: $781 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,419.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,701.80 | 2020-2023 | Tepezza |
| Amgen INC. | $498.36 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $455.17 | 2019-2025 | Rocklatan, Tryptyr, Eysuvis |
| Bausch & Lomb Americas INC. | $420.61 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $356.44 | 2022-2025 | |
| Oyster Point Pharma, INC. | $269.25 | 2022-2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $186.57 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $121.12 | 2023-2024 | Atlas 500 |
| Harrow Eye, LLC | $95.12 | 2024 | Vevye |
| Merz North America, INC. | $83.11 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $66.60 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $65.15 | 2024 | Oxervate |
| Astellas Pharma US INC | $63.15 | 2025 | Izervay |
| Allergan, INC. | $51.95 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $40.80 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $40.00 | 2024-2025 | |
| Thea Pharma INC. | $39.11 | 2023-2025 | Iyuzeh |
| Celularity INC. | $21.48 | 2021 | |
| Merz Pharmaceuticals, LLC | $21.47 | 2021 | |
| Glaukos Corporation | $21.02 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Kala Pharmaceuticals, INC. | $21.01 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.30 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Rayner Intraocular Lenses Limited | $18.66 | 2022 | |
| New World Medical,INC. | $15.85 | 2025 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlene Morales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.